CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
FOR THE PORTIONS MARKED [***]
AGREEMENT BY AND BETWEEN
ARENA PHARMACEUTICALS, INC.
TAIGEN BIOTECHNOLOGY CO., LTD.
TABLE OF CONTENTS
Provisions Within This Agreement Are Deemed "CONFIDENTIAL"
in Accordance With The Terms of Article XI.
Reviewers are advised to confirm with their attorney as to any obligations and/or requirements regarding review
of this Agreement.
This Agreement ("Agreement") is effective as defined below by and between ARENA PHARMACEUTICALS,
INC., a Delaware corporation having a place of business at 6166 Nancy Ridge Drive, San Diego, California,
92121 USA ("Arena"), and TAIGEN BIOTECHNOLOGY CO., LTD., a corporation incorporated as a
company limited by shares in accordance with the Company law of the Republic of China ("TaiGen").
WHEREAS, TaiGen is a start-up biopharmaceutical organization focused on the discovery and development of
WHEREAS, Arena is a publicly traded biopharmaceutical organization (Nasdaq:
ARNA) focused on the discovery and development of innovative therapeutics;
WHEREAS, Arena and TaiGen each desires to enter into this Agreement on the terms and conditions set forth
Article I. Definitions 1
Article II. GPCR Selection By TaiGen 6
Article III. Arena Activities 10
Article IV. TaiGen Activities 11
Article V. License Grant 13
Article VI. Warranties 15
Article VII. Diligence Is Of The Essence 16
Article VIII. TaiGen Royalty Payments 17
Article IX. Arena Royalty Payments 18
Article X. Payment Arrangement